

Triple Drug Combination for Uncontrolled T2DM



In Uncontrolled Type 2 Diabetes

Rx Diet, Exercise &

AffOdapa[®]-SM $\frac{500}{1000}$

Dapagliflozin 10 mg + Sitagliptin 100 mg + Metformin 500/1000 mg Tablets



In Uncontrolled Type 2 Diabetes



Background

Managing hyperglycemia in patients with Type-2 Diabetes Mellitus (T2DM) often requires the use of multiple agents with complementary mechanisms of action. However, many existing treatment combinations are limited by side effects such as hypoglycemia and weight gain, which can hinder effective glycemic and weight control. This highlights the need for newer, more balanced therapeutic options.

A fixed-dose combination of an SGLT-2 inhibitor, a DPP-4 inhibitor, and Metformin offers a rational approach to address these challenges. Clinical studies have shown that combining an SGLT-2 inhibitor with a DPP-4 inhibitor provides superior efficacy when added to metformin compared with monotherapy add-ons, making this triple therapy a **promising option for improved diabetes management**.

Description

- **Affodapa-SM 500:** Tablet contains Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin (Extended Release) 500 mg.
- **Affodapa-SM 1000:** Tablet contains Dapagliflozin 10 mg, Sitagliptin 100 mg, and Metformin (Extended Release) 1000 mg.

Indication

- **Affodapa-SM 500/1000** is indicated as an adjunct to diet and exercise to improve glycemic control in adults with **Uncontrolled Type-2 Diabetes Mellitus**.

Mechanism of Action

- **Sitagliptin:** Inhibits DPP-4, Prevents the breakdown of incretin hormones (GLP-1 and GIP), which enhances insulin secretion and reduces glucagon release after meals.
- **Dapagliflozin:** Inhibits SGLT-2 in the kidneys, reduces glucose reabsorption and increases urinary glucose excretion, thereby lowering blood glucose levels and also supports weight reduction.
- **Metformin:** Reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity by enhancing peripheral glucose uptake and utilization.

Dosage

- The recommended dose is one tablet once daily, or as prescribed by the doctor.

References:
Diabetes Obes Metab. 2020;22:1083–1093.
Diabetes Care 2014;37(3):740–750



Corp. & Regd. Office:

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 Tel.: 011-47589500-51(50 lines)
Web: www.medicamen.com/lifesciences | E-mail: info@medicamenlifesciences.com

I am: _____
 Call me on: _____
 Mail me at: _____

2025 All rights reserved, Medicamen Lifesciences Pvt Ltd